Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.

Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.
复制标题

DOI:
10.1016/j.chembiol.2022.01.001
复制
发表时间:
2022-06-16
影响因子:
8.6
通讯作者:
Corson, Timothy W.
Corson, Timothy W.
中科院分区:
生物学1区
文献类型:
--
作者:
Sishtla, Kamakshi;Lambert-Cheatham, Nathan;Lee, Bit;Han, Duk Hee;Park, Jaehui;Pasha, Sheik Pran Babu Sardar;Lee, Sanha;Kwon, Sangil;Muniyandi, Anbukkarasi;Park, Bomina;Odell, Noa;Waller, Sydney;Park, Il Yeong;Lee, Soo Jae;Seo, Seung-Yong;Corson, Timothy W.

文献摘要

参考文献

被引文献

相似文献

血红素合成酶亚铁螯合酶(FECH)的活性与多种疾病有关。特别是,它是眼睛中新血管形成的介质,因此是预防失明的有吸引力的治疗靶点。然而,没有已知的药物样直接FECH抑制剂。在这里,我们开始使用高通量筛选方法来鉴定FECH活性的有效抑制剂,以鉴定FECH的小分子抑制剂作为潜在的治疗先导物。一类三唑并嘧啶酮类化合物的构效关系研究产生了药物样FECH抑制剂。这些化合物抑制细胞中的FECH,结合共晶结构中的活性位点,并且在多种体外测定中具有抗血管生成作用。这些有前途的化合物之一是在脉络膜新生血管形成的小鼠模型中的体内抗血管生成。这项基础性工作可能是新的治疗药物的基础,不仅可以对抗眼部新生血管,还可以对抗以FECH活性为特征的其他疾病。
Activity of the heme synthesis enzyme ferrochelatase (FECH) is implicated in multiple diseases. In particular, it is a mediator of neovascularization in the eye and thus an appealing therapeutic target for preventing blindness. However, no drug-like direct FECH inhibitors are known. Here, we set out to identify small molecule inhibitors of FECH as potential therapeutic leads using a high throughput screening approach to identify potent inhibitors of FECH activity. A structure-activity relationship study of a class of triazolopyrimidinone hits yielded drug-like FECH inhibitors. These compounds inhibit FECH in cells, bind the active site in cocrystal structures, and are anti-angiogenic in multiple in vitro assays. One of these promising compounds was anti-angiogenic in vivo in a mouse model of choroidal neovascularization. This foundational work may be the basis for new therapeutic agents to combat not only ocular neovascularization, but also other diseases characterized by FECH activity.
MEK通过RSK-ABCB1和HIF-1α-Fech轴减少了癌症特异性PPIX的积累。
DOI: 10.1038/s41598-020-79144-x
发表时间: 2020-12-17
期刊: Scientific reports
影响因子: 4.6
作者:
Chelakkot VS;Liu K;Yoshioka E;Saha S;Xu D;Licursi M;Dorward A;Hirasawa K
通讯作者: Hirasawa K
DOI: 10.1016/s0304-3835(02)00284-7
发表时间: 2002-12-10
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Bhasin, G;Kausar, H;Athar, M
通讯作者: Athar, M
DOI: 10.1038/ja.2008.124
发表时间: 2008-03-01
影响因子: 3.3
作者:
El-Gendy, Mervat M. A.;Shaaban, Mohamed;Laatsch, Hartmut
通讯作者: Laatsch, Hartmut
DOI: 10.1111/cas.12147
发表时间: 2013-06-01
期刊: CANCER SCIENCE
影响因子: 5.7
作者:
Inoue, Keiji;Fukuhara, Hideo;Shuin, Taro
通讯作者: Shuin, Taro
DOI: 10.1021/acschembio.5b01063
发表时间: 2016-05-01
影响因子: 4
作者:
Klaeger, Susan;Gohlke, Bjoern;Kuster, Bernhard
通讯作者: Kuster, Bernhard